Thymosin beta-4 Recruiting Phase 3 Trials for Neurotrophic Keratopathy Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Recruiting | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT05555589 | Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |